Compare Automatic Data Processing Inc (ADP) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs Mesoblast Limited — how do they compare? Automatic Data Processing Inc trades at $270.31 (market cap $107.69B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Automatic Data Processing Inc is far larger — about 48.7× Mesoblast Limited's market cap, and Automatic Data Processing Inc pays a 2.51% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| ADP | MESO | |
|---|---|---|
Market Cap | $107.69B | $2.21B |
Sector | Industrials | Technology |
52-Week High | $309.03 | $20.96 |
52-Week Low | $188.79 | $12.88 |
Enterprise Value | $108.73B | $2.21B |
Dividend Yield | 2.51% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
